RxDoctor Payments Data

Donald Lazas

Hermitage, TNNPI 1427055326

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,100 of the $3,148 with a category attached, or 66.7%. Novo Nordisk accounts for 66.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $2,203 and has fallen 98.6% since, to $31 in 2024.

$3,148in general payments, 2019–2025

Across 43 payments — averaging $73.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Novartis$358
  • AbbVie$173
  • Bristol Myers Squibb$113
  • Johnson & Johnson$103
  • Ferring Pharmaceuticals Inc.$64
  • plus $238 from 9 others
$1,060,062in research payments, 2019–2025

Across 244 payments — averaging $4344.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$577K
  • Novartis$410K
  • Alnylam Pharmaceuticals Inc.$41K
  • Novo Nordisk AS$32K

What the payments were for

  • Consulting fees$2,10067%
  • Travel & lodging$2267%
  • Food & beverage$78825%
  • Other$341%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pantoprazole Sodium11$294

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →